Neonatal Jaundice: Phototherapy Protocols And Follow-Up

Neonatal jaundice is common, but visible yellowing is only an initial clinical sign. The underlying bilirubin concentration, the infant’s gestational age, age in hours, rate of rise, feeding pattern, and medical risk factors determine whether observation is appropriate or treatment is urgent. A safe protocol therefore combines assessment, laboratory measurement, treatment thresholds, and planned reassessment.

Unconjugated hyperbilirubinemia usually results from increased red-cell turnover and the newborn liver’s limited ability to process bilirubin. Most cases are transitional and resolve with effective feeding. However, rapidly increasing bilirubin or prolonged exposure to high levels can cause acute bilirubin encephalopathy and, in severe cases, permanent neurological injury.

The principles below reflect widely used neonatal practice, including hour-specific treatment curves and risk-based follow-up. Local hospital guidance should take priority, particularly for premature infants, babies with hemolysis, and newborns who require intensive care. The FAOPS 2020 archive provides historical context for the perinatal medicine community in which these clinical discussions take place.

Early Assessment And Risk Stratification

Every newborn should receive a structured jaundice assessment before discharge. Clinicians consider the timing of visible jaundice, skin and scleral color, feeding effectiveness, urine and stool output, weight change, bruising, cephalohematoma, and family history. Jaundice appearing during the first 24 hours is more concerning than the usual physiological pattern and requires prompt serum bilirubin testing.

A transcutaneous bilirubin measurement can provide a convenient screening estimate, but a total serum bilirubin level is needed when the screening value approaches the treatment threshold, exceeds the device’s reliable range, or conflicts with the clinical picture. The result should be interpreted according to the infant’s postnatal age in hours rather than against a single universal number.

Risk factors that lower the treatment threshold include gestational age below 38 weeks, isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase deficiency, sepsis, significant clinical instability, and suspected rapid bilirubin production. Direct or conjugated bilirubin should be measured when jaundice is prolonged, atypical, or accompanied by pale stools, dark urine, hepatosplenomegaly, or poor growth.

Choosing A Phototherapy Protocol

Phototherapy converts bilirubin in the skin into water-soluble photoisomers that can be eliminated without normal hepatic conjugation. Intensive phototherapy should expose as much skin as safely possible to an effective blue-light spectrum, generally around 460–490 nanometers. The equipment must be positioned according to manufacturer instructions, and irradiance should be checked with an appropriate meter when available.

Treatment decisions use a graph or electronic calculator that combines total serum bilirubin, age in hours, and gestational age. The American Academy of Pediatrics 2022 guideline applies primarily to infants born at 35 weeks or later; preterm infants need protocols designed for their gestational age and clinical condition. A bilirubin value should never be interpreted without recording the exact age at sampling.

During phototherapy, eye protection must be correctly fitted, temperature monitored, and hydration assessed. Breastfeeding should continue whenever possible, with practical support to improve milk transfer. Temporary supplementation may be considered when intake is inadequate, weight loss is excessive, dehydration is present, or bilirubin continues to rise. Routine interruption for feeding is often acceptable in a stable infant, but prolonged breaks should be avoided when bilirubin is near an escalation threshold.

Treatment Thresholds In Clinical Practice

The treatment threshold is not a fixed diagnostic boundary. It represents the point at which the expected benefit of reducing bilirubin outweighs the burdens and potential harms of phototherapy. A newborn who is clinically unstable or has a neurotoxicity risk factor may require treatment at a lower bilirubin level than a well infant of the same age and gestational maturity.

A useful protocol records the bilirubin trend as well as the absolute value. A rapid rise, particularly when hemolysis is suspected, should prompt urgent review even if the current result remains below the phototherapy line. Blood group testing, direct antiglobulin testing, reticulocyte count, blood film, and enzyme testing may be appropriate depending on the clinical setting and background.

When bilirubin approaches the escalation-of-care range, management must become urgent. Intensive phototherapy is continued while the team evaluates for hemolysis, sepsis, dehydration, and other contributors. Intravenous immunoglobulin may be considered in selected cases of isoimmune hemolysis, while exchange transfusion is reserved for severe or rapidly rising bilirubin despite intensive treatment, or for signs of acute bilirubin neurotoxicity.

Feeding, Hydration, And Family Participation

Poor intake increases enterohepatic circulation and reduces bilirubin elimination. A feeding assessment should examine latch, swallowing, feeding frequency, maternal milk production, and the infant’s output. Weight trends, urine concentration, stool transition, and alertness provide practical clues, although none replaces bilirubin measurement.

Families need clear explanations about why treatment is recommended, how the light works, and why eye protection and monitoring are necessary. They should be told that jaundice can deepen even when an infant appears otherwise comfortable. Involving parents in feeding, comforting, diaper changes, and skin-to-skin contact can preserve attachment while treatment continues. Guidance on family-centered NICU care is especially relevant when phototherapy occurs in a neonatal unit.

Home phototherapy may be suitable only for carefully selected, clinically well infants with reliable caregivers, appropriate equipment, a bilirubin level safely below escalation thresholds, and assured next-day measurement or clinical review. It is generally unsuitable when there is hemolysis, prematurity requiring close observation, significant dehydration, rapidly rising bilirubin, or uncertainty about follow-up.

Stopping Treatment And Checking For Rebound

Phototherapy can usually stop when the bilirubin has fallen sufficiently below the relevant treatment line and the infant is clinically stable. The exact margin depends on the guideline, gestational age, cause of jaundice, and whether treatment began early. Infants with hemolytic disease or a bilirubin level close to the treatment threshold are more likely to experience rebound hyperbilirubinemia.

A repeat bilirubin after stopping phototherapy is not identical for every newborn. Some infants need measurement several hours after treatment, while others can be assessed the following day or through scheduled outpatient testing. Early follow-up is particularly important when phototherapy started before 48 hours of age, the direct antiglobulin test is positive, gestational age is low, or the bilirubin rose rapidly before treatment.

Discharge documentation should include the most recent bilirubin, the infant’s age at measurement, treatment dates, feeding plan, weight information, and the time and location of the next assessment. Families should receive written instructions to seek immediate medical attention for marked sleepiness, difficulty feeding, a weak cry, abnormal tone, arching, fever, fewer wet diapers, or worsening yellow coloration.

Follow-Up Beyond The Newborn Period

Postdischarge surveillance begins with a bilirubin result interpreted against the phototherapy threshold. The closer the value is to that threshold, the sooner follow-up should occur. A well-organized plan identifies who will review the result, who will arrange repeat testing, and how the family can obtain help outside normal clinic hours.

Persistent jaundice needs a different line of investigation from ordinary early physiological jaundice. Breast milk jaundice can continue in an otherwise thriving infant, but prolonged jaundice should still prompt evaluation for conjugated hyperbilirubinemia, hypothyroidism, infection, metabolic disease, and anatomical obstruction. Pale or acholic stools and dark urine are warning signs that require urgent assessment rather than reassurance.

Neurodevelopmental follow-up is appropriate after severe hyperbilirubinemia, exchange transfusion, acute neurological signs, or significant prematurity. Monitoring may include hearing assessment, muscle tone, motor development, feeding skills, and language milestones. Early referral to developmental, audiology, or neurology services can reduce delays when concerns emerge.

Practical Recommendations For Safer Care

• Record gestational age, postnatal age in hours, bilirubin value, feeding status, and neurotoxicity risk factors at every decision point.
• Use a validated local phototherapy nomogram or electronic calculator instead of relying on visual jaundice severity.
• Measure serum bilirubin promptly for jaundice in the first 24 hours, a value near the treatment line, or an unexpected clinical deterioration.
• Support effective feeding while avoiding unsafe delays in intensive phototherapy or escalation of care.
• Give families a written follow-up appointment, warning signs, and a clear route for urgent advice before discharge.

Effective management depends on continuity between the birth facility, neonatal team, primary care service, laboratory, and family. Phototherapy is highly effective when delivered at the right intensity and at the right time, but safe care also requires attention to feeding, hemolysis, rebound levels, and long-term development.

Use these principles alongside current national guidance and your institution’s neonatal protocol. Review bilirubin results promptly, document the follow-up plan, and arrange timely clinical assessment whenever a newborn’s jaundice is early, worsening, prolonged, or accompanied by feeding difficulty or neurological signs.